<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23332" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ibutilide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Szymanski</surname>
            <given-names>Michael W.</given-names>
          </name>
          <aff>Stony Brook University-Southampton Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pellegrini</surname>
            <given-names>Mark V.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cassagnol</surname>
            <given-names>Manouchkathe</given-names>
          </name>
          <aff>St. John's University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Szymanski declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Pellegrini declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manouchkathe Cassagnol declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23332.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Ibutilide is a class III antiarrhythmic medication approved by the US Food and Drug Administration (FDA)&#x000a0;for converting acute atrial flutter and atrial fibrillation to normal sinus rhythm. Studies indicate ibutilide's&#x000a0;greater efficacy in treating atrial flutter than atrial fibrillation.&#x000a0;In addition to its FDA-approved indications, ibutilide is commonly used off-label as a pretreatment for electro-cardioversion and may also be administered post-cardioversion to prevent recurrent atrial fibrillation. Moreover, ibutilide administration might be necessary following surgery.&#x000a0;Ibutilide functions as a potassium channel blocker, extending phase 3 of the cardiac action potential. This leads to heightened refractoriness of atrial and ventricular myocytes, along with the atrioventricular node and the His-Purkinje system.</p>
        <p>This activity comprehensively explores ibutilide's indications, mechanism of action, adverse event profile, pharmacological&#x000a0;properties, essential monitoring, and drug interactions to ensure its safe and effective utilization in clinical settings. The knowledge gained from this activity helps establish the competency of the interprofessional healthcare team in proficiently managing cardiac disorders responsive to this therapeutic approach, thereby optimizing patient outcomes.&#x000a0;Moreover, this activity also allows the healthcare team to make informed decisions in managing acute atrial arrhythmias by providing them with the necessary tools to tailor treatment strategies and mitigate potential risks, thereby fostering a collaborative approach to managing cardiac conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the FDA-approved indications for ibutilide, such as managing acute atrial flutter and atrial fibrillation, as well as off-label uses, including pretreatment for electro-cardioversion and post-cardioversion therapy.</p></list-item><list-item><p>Screen patients for contraindications to ibutilide therapy, including hypersensitivity reactions and underlying cardiac conditions such as long QT syndrome.</p></list-item><list-item><p>Apply evidence-based guidelines and recommendations when selecting ibutilide as part of a comprehensive management approach for atrial flutter and fibrillation.</p></list-item><list-item><p>Coordinate with other healthcare providers to ensure continuity of care for patients receiving ibutilide, including transitions between inpatient and outpatient settings.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23332&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23332">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23332.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ibutilide is a class III antiarrhythmic medication approved by the US Food and Drug Administration (FDA)&#x000a0;for converting acute atrial flutter and atrial fibrillation to normal sinus rhythm.<xref ref-type="bibr" rid="article-23332.r1">[1]</xref>&#x000a0;Research indicates ibutilide's greater efficacy in treating atrial flutter compared to atrial fibrillation.<xref ref-type="bibr" rid="article-23332.r2">[2]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The FDA has approved ibutilide for the conversion of recent onset atrial flutter and atrial fibrillation to sinus rhythm.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>In addition to its FDA-approved indications, ibutilide is commonly used off-label as a pretreatment for electro-cardioversion. Pretreatment with ibutilide, sotalol, or dofetilide may help conversion to&#x000a0;normal sinus rhythm&#x000a0;in cases of refractory atrial fibrillation. Ibutilide may also be administered post-cardioversion to prevent recurrent atrial fibrillation.<xref ref-type="bibr" rid="article-23332.r3">[3]</xref></p>
        <p>Ibutilide administration may also be necessary following surgery.<xref ref-type="bibr" rid="article-23332.r4">[4]</xref></p>
      </sec>
      <sec id="article-23332.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ibutilide functions as a potassium channel blocker, extending phase 3 of the cardiac action potential. This leads to increased refractoriness of atrial and ventricular myocytes, along with the atrioventricular node and the His-Purkinje system.<xref ref-type="bibr" rid="article-23332.r1">[1]</xref></p>
        <p>The cardiac action potential of ibutilide is divided into 5 stages, as mentioned below.</p>
        <p>
<bold>Phase 0: Rapid Depolarization Phase</bold>
</p>
        <p>During phase 0, fast sodium channels open when the cell reaches the threshold, which results in a rapid depolarization of the myocyte&#x000a0;that continues until inactivation gates close,&#x000a0;ceasing sodium conductance. A time-dependent mechanism mediates the closure of inactivation gates. The reopening of inactivation gates occurs during cell repolarization, specifically upon re-approaching the threshold.</p>
        <p>
<bold>Phase 1: Early Repolarization&#x000a0;Phase</bold>
</p>
        <p>Potassium channels open, causing an efflux of potassium called the transient outward current <italic toggle="yes">(ito)</italic>. The end of phase 1 is characterized by a balance between calcium and potassium efflux, leading to the plateau phase.</p>
        <p>
<bold>Phase 2: Plateau&#x000a0;Phase</bold>
</p>
        <p>The plateau phase consists of a balance between calcium influx and potassium efflux. The calcium channels are L-type dihydropyridine-receptor channels that inactivate slowly. Drugs that alter calcium conductance modulate this phase and belong to Class 4 of the Vaughn-Williams classification system. During the latter stages of the plateau phase, delayed rectifying potassium channels (<italic toggle="yes">iKr</italic>) open and allow the myocyte to begin repolarization as the calcium current declines.</p>
        <p>
<bold>Phase 3: Repolarization&#x000a0;Phase</bold>
</p>
        <p>In phase 3 of the cardiac action potential, potassium efflux exceeds the inward calcium current, causing repolarization. When&#x000a0;positively charged potassium&#x000a0;ions&#x000a0;move out of the cell, it restores the negative potential of the cardiac myocyte. Three potassium channels are involved in the repolarization phase. While the cell membrane remains depolarized, <italic toggle="yes">iKr&#x000a0;</italic>and <italic toggle="yes">ito&#x000a0;</italic>are the major contributors to potassium efflux. As the myocyte approaches the threshold, the inwardly rectifying current (<italic toggle="yes">iK1</italic>) channels open and contribute to repolarization. Although <italic toggle="yes">iK1&#x000a0;</italic>channels are termed "inwardly rectifying," potassium efflux occurs due to the electrochemical potential of potassium derived from the cord conductance equation.</p>
        <p>Ibutilide is a potassium-blocking agent primarily affecting delayed rectifying potassium channels (<italic toggle="yes">iKr</italic>). By blocking potassium channels, phase 3 is lengthened, prolonging the QTc interval and increasing the refractoriness of the atrial and ventricular myocytes. When a myocyte is in the absolute refractory period, a subsequent action potential cannot be propagated, causing a decrease in the heart rate of patients presenting with tachydysrhythmias.<xref ref-type="bibr" rid="article-23332.r5">[5]</xref>&#x000a0;Conversion to sinus rhythm occurs in less than 90 minutes after the start of infusion.&#x000a0;Ibutilide has also been shown to activate a slow, delayed, inward sodium current during the early stages of repolarization. However, the blockade of <italic toggle="yes">iKr</italic> channels is the major contributor to&#x000a0;the antiarrhythmic properties.<xref ref-type="bibr" rid="article-23332.r6">[6]</xref>&#x000a0;</p>
        <p>
<bold>Phase 4: Resting&#x000a0;Phase</bold>
</p>
        <p>Na+/K+ ATPase dominates phase 4. For every&#x000a0;3 Na+ ions pumped out of the cell,&#x000a0;2 K+ ions are pumped in, resulting in a negative resting membrane potential.&#x000a0;A primary active transporter called the calcium ATPase re-sequesters most of the intracellular calcium into the sarcoplasmic reticulum. The regulation of sarcoplasmic calcium ATPase occurs by an intracellular protein called phospholamban. When phospholamban undergoes phosphorylation via protein kinase A (PKA), the calcium ATPase is active and incorporates cytosolic calcium ions into the sarcoplasmic reticulum. More calcium is released into the cytosol during the next action potential, causing increased contractility. When phospholamban is de-phosphorylated, it inhibits the sarcoplasmic calcium ATPase.</p>
        <p>The remaining calcium ions get pumped out of the myocytes by secondary active transport through the Na+/Ca++ exchanger.&#x000a0;Cardiac myocyte Na+/K+ ATPase is inhibited pharmacologically by the cardiac glycosides (digoxin). Inhibition of the Na+/K+ ATPase causes an increase in intracellular Na+ ions and leads to a series of biochemical changes, beginning with the reverse action of membrane-bound Na+/Ca++ exchangers. The change in polarity of Na+/Ca++ exchangers causes an efflux of Na+ and an influx of Ca++ to restore the resting membrane potential without Na+/K+ ATPase activity. The increased concentration of intracellular calcium is responsible for the positive inotropic properties of digoxin therapy.<xref ref-type="bibr" rid="article-23332.r7">[7]</xref></p>
        <p>
<bold>Notable Electrocardiographic Changes</bold>
</p>
        <p>Notable electrocardiographic (ECG) changes associated with ibutilide administration include slowing heart rate and prolonging the QT interval, which carries a risk of developing torsades de pointes.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Ibutilide is rapidly and completely absorbed following intravenous (IV) administration.</p>
        <p><bold>Distribution:</bold> Ibutilide exhibits a distribution volume of 11 L/kg.</p>
        <p><bold>Metabolism:</bold> Ibutilide undergoes hepatic metabolism, yielding 8 metabolites, 1 of which is active. This metabolism primarily involves the CYP450 enzyme system in the liver. The drug's half-life ranges from 2 to 12 hours, with an average of 6 hours.</p>
        <p><bold>Elimination:</bold> The primary routes of elimination for ibutilide are urinary (82%) and fecal excretion (19%).</p>
      </sec>
      <sec id="article-23332.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Ibutilide is available and administered as an IV solution of 1 mg/10 mL.</p>
        <list list-type="bullet">
          <list-item>
            <p>For patients with a body weight of less than 60 kg, the ibutilide&#x000a0;dosage is 0.01 mg/kg administered over 10 minutes. The dosage may be repeated if the patient does not respond within 10 minutes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients with a body weight of&#x000a0;more than 60 kg, the dosage is 1 mg administered over 10 minutes. The dosage may be repeated if the patient does not respond within 10 minutes.&#x000a0;</p>
          </list-item>
        </list>
        <p>Drug administration can be either diluted or undiluted. Infusion should be stopped upon resolution of the presenting arrhythmia or new-onset ventricular tachycardia. If the arrhythmia fails to diminish within 10 minutes following the infusion, another dose may be administered over 10 minutes.&#x000a0;</p>
        <p>Magnesium enhances the ability of ibutilide to convert atrial flutter or fibrillation to normal sinus rhythm. Magnesium can also help prevent prolongation of the QT interval, and it sees frequent use in treating torsades de pointes in hemodynamically stable patients.<xref ref-type="bibr" rid="article-23332.r8">[8]</xref><xref ref-type="bibr" rid="article-23332.r9">[9]</xref><xref ref-type="bibr" rid="article-23332.r10">[10]</xref>&#x000a0;Ibutilide can be safely administered alongside class 1C antiarrhythmics, as these medications do not impact the QT interval.<xref ref-type="bibr" rid="article-23332.r11">[11]</xref>&#x000a0;Moreover, the risk of arrhythmia does not escalate when ibutilide is administered concurrently with amiodarone.<xref ref-type="bibr" rid="article-23332.r12">[12]</xref></p>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Patients with&#x000a0;hepatic impairment do not require dosage adjustment.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;No dosage adjustments are necessary for patients with renal impairment, though dosing for dialysis patients remains undefined.</p>
        <p><bold>Pregnant considerations:</bold> Clinicians should carefully assess risks versus benefits for pregnant patients. Although IV ibutilide is generally effective and may be considered, experience during pregnancy is limited.<xref ref-type="bibr" rid="article-23332.r13">[13]</xref> However, based on limited data from human studies, the likelihood of fetal harm is low.&#x000a0;</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Nursing mothers can use ibutilide while breastfeeding, although it is not recommended.<xref ref-type="bibr" rid="article-23332.r14">[14]</xref>&#x000a0;Therefore, breastfeeding should be discouraged, as limited data exist regarding the drug's effect on milk production.</p>
        <p><bold>Pediatric patients:</bold> Ibutilide lacks approved indications for pediatric use, and its safety and efficacy in this population remain undetermined.</p>
        <p><bold>Older patients:</bold> For older patients, treatment should be initiated at the lower end of the dosing spectrum, and healthcare providers should vigilantly monitor patient response.</p>
      </sec>
      <sec id="article-23332.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>According to the Institute for Safe Medication Practices (ISMP), ibutilide carries a heightened risk of causing significant patient harm, including potentially fatal arrhythmias. Thus, clinicians must consistently assess the balance between benefits and risks when contemplating the use of this agent.</p>
        <p>
<bold>Cardiac Adverse Effects</bold>
</p>
        <p>Cardiac adverse effects associated with this medication include nonsustained monomorphic ventricular tachycardia, premature ventricular contractions, nonsustained polymorphic ventricular tachycardia, atrioventricular block, bundle branch block, hypotension, torsades de pointes, prolonged QT interval, hypertension, palpitations, and bradycardia.</p>
        <p>
<bold>Extracardiac Adverse Effects</bold>
</p>
        <p>Extracardiac adverse effects include nausea, headache, renal failure, and erythematous rash.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Category X (avoid):</bold>&#x000a0;The medications that are classified as Category X and&#x000a0;should&#x000a0;be avoided include amifampridine, fingolimod, hydroxychloroquine, macimorelin, mifepristone, mizolastine, probucol, promazine, vinflunine, cisapride, dronedarone, levoketoconazole, ziprasidone, thioridazine, pimozide, and fingolimod.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Category D (modify regimen):&#x000a0;</bold>Indapamide falls under Category D, indicating the need to modify the regimen cautiously.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Category C (monitor):&#x000a0;</bold>The medications classified as Category&#x000a0;C require close monitoring and careful consideration in their administration, which include bilastine, fluoxetine, pefloxacin, teneligliptin, and xipamide.</p>
          </list-item>
        </list>
        <p>Before administering ibutilide, it is recommended to conduct a medication reconciliation involving the ordering clinician and a clinical pharmacist due to the potential for interactions with many other drugs.</p>
      </sec>
      <sec id="article-23332.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warning</bold>
</p>
        <p><bold>Life-threatening arrhythmias:</bold> Ibutilide poses a risk of life-threatening arrhythmias, notably sustained polymorphic ventricular tachycardia, often associated with QT prolongation (torsades de pointes), although instances have been reported without documented QT prolongation.&#x000a0;</p>
        <p><bold>Choosing patients:</bold>&#x000a0;Patient selection is crucial, particularly for individuals with chronic atrial fibrillation, as they often exhibit a strong tendency to revert&#x000a0;following conversion to sinus rhythm, and maintenance therapies carry inherent risks. Therefore, patients should be meticulously chosen based on the anticipated advantages of maintaining sinus rhythm, which should outweigh the immediate risks associated with ibutilide and the potential hazards of maintenance therapy.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ibutilide is contraindicated in individuals with hypersensitivity to ibutilide or any compound in the formulation, congenital long QT syndrome, a history of polymorphic ventricular tachycardia, uncorrected electrolyte abnormalities, sinus node disease, and structural cardiac disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Caution should be exercised in individuals with QT prolongation, a family history of QT prolongation, recent myocardial infarction, bradycardia, congestive heart failure, and those aged 65 and older. Caution is also warranted in patients with hepatic impairment, as liver enzymes metabolize the drug, and no dosing recommendations exist.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23332.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients should undergo continuous ECG monitoring for 4 hours after discontinuing ibutilide infusion or until the QTc interval returns to normal (&#x0003c;440 ms). In cases where arrhythmia persists, monitoring should extend beyond 4 hours, particularly if hepatic function is impaired. Rapid availability of equipment for managing potentially fatal arrhythmias is essential. Baseline electrolyte levels, especially magnesium, should be established.</p>
      </sec>
      <sec id="article-23332.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Currently, the antidote for ibutilide does not exist. In animal models, acute overdose&#x000a0;has caused central nervous system (CNS) toxicity,&#x000a0;including CNS depression, rapid gasping, and convulsions.<xref ref-type="bibr" rid="article-23332.r15">[15]</xref></p>
      </sec>
      <sec id="article-23332.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>As per the ISMP, ibutilide poses a high risk of causing significant patient harm. The interprofessional healthcare team, comprising physicians and specialists, physician assistants, nurse practitioners, pharmacists, and nurses, must collectively monitor these patients for potential adverse cardiac and extracardiac events. Due to the potential for dangerous arrhythmias associated with ibutilide, pharmacists should meticulously review all ibutilide orders and conduct medication reconciliation to identify and mitigate possible drug-drug interactions.</p>
        <p>In most cases, the IV will be administered by nursing staff, who can verify the administration duration and dose while closely monitoring for any adverse effects. Should any concerns arise, nurses must promptly report them to the interprofessional healthcare team for further clinical evaluation and intervention. Ordering clinicians should rely on nurses and pharmacists to ensure optimal therapy results, fostering a collaborative team environment.&#x000a0;</p>
      </sec>
      <sec id="article-23332.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23332&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23332">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23332/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23332">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23332.s11">
        <title>References</title>
        <ref id="article-23332.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Ibutilide.</article-title>
            <source>Circulation</source>
            <year>1998</year>
            <month>Feb</month>
            <day>10</day>
            <volume>97</volume>
            <issue>5</issue>
            <fpage>493</fpage>
            <page-range>493-7</page-range>
            <pub-id pub-id-type="pmid">9490245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kowey</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Stoenescu</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Selection of drugs in pursuit of a rhythm control strategy.</article-title>
            <source>Prog Cardiovasc Dis</source>
            <year>2005</year>
            <season>Sep-Oct</season>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>139</fpage>
            <page-range>139-45</page-range>
            <pub-id pub-id-type="pmid">16253653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oral</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Michaud</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Strickberger</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Morady</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Jun</month>
            <day>17</day>
            <volume>340</volume>
            <issue>24</issue>
            <fpage>1849</fpage>
            <page-range>1849-54</page-range>
            <pub-id pub-id-type="pmid">10369847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VanderLugt</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Mattioni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Denker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Torchiana</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ahern</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wakefield</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Kowey</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery.</article-title>
            <source>Circulation</source>
            <year>1999</year>
            <month>Jul</month>
            <day>27</day>
            <volume>100</volume>
            <issue>4</issue>
            <fpage>369</fpage>
            <page-range>369-75</page-range>
            <pub-id pub-id-type="pmid">10421596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Snyders</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Roden</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects.</article-title>
            <source>Circulation</source>
            <year>1995</year>
            <month>Mar</month>
            <day>15</day>
            <volume>91</volume>
            <issue>6</issue>
            <fpage>1799</fpage>
            <page-range>1799-806</page-range>
            <pub-id pub-id-type="pmid">7882490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>1992</year>
            <month>Jul</month>
            <volume>262</volume>
            <issue>1</issue>
            <fpage>99</fpage>
            <page-range>99-108</page-range>
            <pub-id pub-id-type="pmid">1320693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whayne</surname>
                <given-names>TF</given-names>
              </name>
            </person-group>
            <article-title>Clinical Use of Digitalis: A State of the Art Review.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>427</fpage>
            <page-range>427-440</page-range>
            <pub-id pub-id-type="pmid">30066080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patsilinakos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Christou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kafkas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nikolaou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Antonatos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Katsanos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spanodimos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Babalis</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent.</article-title>
            <source>Am J Cardiol</source>
            <year>2010</year>
            <month>Sep</month>
            <day>01</day>
            <volume>106</volume>
            <issue>5</issue>
            <fpage>673</fpage>
            <page-range>673-6</page-range>
            <pub-id pub-id-type="pmid">20723644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caron</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Kluger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tsikouris</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ritvo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kalus</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide.</article-title>
            <source>Pharmacotherapy</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>296</fpage>
            <page-range>296-300</page-range>
            <pub-id pub-id-type="pmid">12627926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of class III antiarrhythmics and magnesium combination therapy for atrial fibrillation.</article-title>
            <source>Pharm Pract (Granada)</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>65</fpage>
            <page-range>65-71</page-range>
            <pub-id pub-id-type="pmid">24155819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hongo</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Themistoclakis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raviele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bonso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rossillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Glatter</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Scheinman</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2004</year>
            <month>Aug</month>
            <day>18</day>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>864</fpage>
            <page-range>864-8</page-range>
            <pub-id pub-id-type="pmid">15312873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glatter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Modin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kayser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scheinman</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Chemical cardioversion of atrial fibrillation or flutter with ibutilide in patients receiving amiodarone therapy.</article-title>
            <source>Circulation</source>
            <year>2001</year>
            <month>Jan</month>
            <day>16</day>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>253</fpage>
            <page-range>253-7</page-range>
            <pub-id pub-id-type="pmid">11208685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kockova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kocka</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fahy</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Ibutilide-induced cardioversion of atrial fibrillation during pregnancy.</article-title>
            <source>J Cardiovasc Electrophysiol</source>
            <year>2007</year>
            <month>May</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>545</fpage>
            <page-range>545-7</page-range>
            <pub-id pub-id-type="pmid">17286570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>European Society of Gynecology (ESG)</collab>
              <collab>Association for European Paediatric Cardiology (AEPC)</collab>
              <collab>German Society for Gender Medicine (DGesGM)</collab>
              <name>
                <surname>Regitz-Zagrosek</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Blomstrom Lundqvist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cifkova</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Foidart</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gohlke-Baerwolf</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gorenek</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Iung</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maas</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Morais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nihoyannopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Presbitero</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roos-Hesselink</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Schaufelberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seeland</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Torracca</surname>
                <given-names>L</given-names>
              </name>
              <collab>ESC Committee for Practice Guidelines</collab>
            </person-group>
            <article-title>ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).</article-title>
            <source>Eur Heart J</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>24</issue>
            <fpage>3147</fpage>
            <page-range>3147-97</page-range>
            <pub-id pub-id-type="pmid">21873418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23332.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marks</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Terry</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Developmental toxicity of ibutilide fumarate in rats after oral administration.</article-title>
            <source>Teratology</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>157</fpage>
            <page-range>157-64</page-range>
            <pub-id pub-id-type="pmid">8987159</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
